Literature DB >> 21681798

Alternative processing of γ-secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ-secretase dysfunction.

Saori Hata1, Sayaka Fujishige, Yoichi Araki, Miyako Taniguchi, Katsuya Urakami, Elaine Peskind, Hiroyasu Akatsu, Masahiko Araseki, Kazuo Yamamoto, Ralph N Martins, Masahiro Maeda, Masaki Nishimura, Allan Levey, Kathryn A Chung, Thomas Montine, James Leverenz, Anne Fagan, Alison Goate, Randall Bateman, David M Holtzman, Tohru Yamamoto, Tadashi Nakaya, Sam Gandy, Toshiharu Suzuki.   

Abstract

OBJECTIVE: The most common pathogenesis for familial Alzheimer's disease (FAD) involves misprocessing (or alternative processing) of the amyloid precursor protein (APP) by γ-secretase due to mutations of the presenilin 1 (PS1) gene. This misprocessing/alternative processing leads to an increase in the ratio of the level of a minor γ-secretase reaction product (Aβ42) to that of the major reaction product (Aβ40). Although no PS1 mutations are present, altered Aβ42/40 ratios are also observed in sporadic Alzheimer's disease (SAD), and these altered ratios apparently reflect deposition of Aβ42 as amyloid.
METHODS: Using immunoprecipitation-mass spectrometry with quantitative accuracy, we analyzed in the cerebrospinal fluid (CSF) of various clinical populations the peptide products generated by processing of not only APP but also an unrelated protein, alcadein (Alc). Alc undergoes metabolism by the identical APP α-secretases and γ-secretases, yielding a fragment that we have named p3-Alc(α) because of the parallel genesis of p3-Alc(α) peptides and the p3 fragment of APP. As with Aβ, both major and minor p3-Alc(α) s are generated. We studied the alternative processing of p3-Alc(α) in various clinical populations.
RESULTS: We previously reported that changes in the Aβ42/40 ratio showed covariance in a linear relationship with the levels of p3-Alc(α) [minor/major] ratio in media conditioned by cells expressing FAD-linked PS1 mutants. Here we studied the speciation of p3-Alc(α) in the CSF from 3 groups of human subjects (n = 158): elderly nondemented control subjects; mild cognitive impairment (MCI) subjects with a clinical dementia rating (CDR) of 0.5; SAD subjects with CDR of 1.0; and other neurological disease (OND) control subjects. The CSF minor p3-Alc(α) variant, p3-Alc(α) 38, was elevated (p < 0.05) in MCI subjects or SAD subjects, depending upon whether the data were pooled and analyzed as a single cohort or analyzed individually as 3 separate cohorts.
INTERPRETATION: These results suggest that some SAD may involve alternative processing of multiple γ-secretase substrates, raising the possibility that the molecular pathogenesis of SAD might involve γ-secretase dysfunction.
Copyright © 2010 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681798      PMCID: PMC3306841          DOI: 10.1002/ana.22343

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

Review 1.  The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.

Authors:  Sam Gandy
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

2.  Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.

Authors:  Thomas Kukar; Michael Paul Murphy; Jason L Eriksen; Sarah A Sagi; Sascha Weggen; Tawnya E Smith; Thomas Ladd; Murad A Khan; Rajashaker Kache; Jenny Beard; Mark Dodson; Sami Merit; Victor V Ozols; Panos Z Anastasiadis; Pritam Das; Abdul Fauq; Edward H Koo; Todd E Golde
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

Review 3.  Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis.

Authors:  Scott A Small; Sam Gandy
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

4.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

5.  Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease.

Authors:  S Lammich; E Kojro; R Postina; S Gilbert; R Pfeiffer; M Jasionowski; C Haass; F Fahrenholz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 6.  ADAMs family members as amyloid precursor protein alpha-secretases.

Authors:  Tobias M J Allinson; Edward T Parkin; Anthony J Turner; Nigel M Hooper
Journal:  J Neurosci Res       Date:  2003-11-01       Impact factor: 4.164

7.  Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.

Authors:  D R Borchelt; G Thinakaran; C B Eckman; M K Lee; F Davenport; T Ratovitsky; C M Prada; G Kim; S Seekins; D Yager; H H Slunt; R Wang; M Seeger; A I Levey; S E Gandy; N G Copeland; N A Jenkins; D L Price; S G Younkin; S S Sisodia
Journal:  Neuron       Date:  1996-11       Impact factor: 17.173

8.  Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor.

Authors:  J D Buxbaum; K N Liu; Y Luo; J L Slack; K L Stocking; J J Peschon; R S Johnson; B J Castner; D P Cerretti; R A Black
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

9.  Coordinated metabolism of Alcadein and amyloid beta-protein precursor regulates FE65-dependent gene transactivation.

Authors:  Yoichi Araki; Naomi Miyagi; Naoko Kato; Tomohiro Yoshida; Sachiyo Wada; Masaki Nishimura; Hiroto Komano; Tohru Yamamoto; Bart De Strooper; Kazuo Yamamoto; Toshiharu Suzuki
Journal:  J Biol Chem       Date:  2004-03-22       Impact factor: 5.157

10.  The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system.

Authors:  Kanta Yanagida; Masayasu Okochi; Shinji Tagami; Taisuke Nakayama; Takashi S Kodama; Kouhei Nishitomi; Jingwei Jiang; Kohji Mori; Shin-Ichi Tatsumi; Tetsuaki Arai; Takeshi Ikeuchi; Kensaku Kasuga; Takahiko Tokuda; Masaki Kondo; Masaki Ikeda; Kentaro Deguchi; Hiroaki Kazui; Toshihisa Tanaka; Takashi Morihara; Ryota Hashimoto; Takashi Kudo; Harald Steiner; Christian Haass; Kuniaki Tsuchiya; Haruhiko Akiyama; Ryozo Kuwano; Masatoshi Takeda
Journal:  EMBO Mol Med       Date:  2009-07       Impact factor: 12.137

View more
  19 in total

1.  Peering inside Alzheimer's brains.

Authors:  Gunjan Sinha
Journal:  Nat Biotechnol       Date:  2011-05       Impact factor: 54.908

2.  γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.

Authors:  Fei Liu; Zhi-Qin Xue; Si-Hao Deng; Xiong Kun; Xue-Gang Luo; Peter R Patrylo; Gregory M Rose; Huaibin Cai; Robert G Struble; Yan Cai; Xiao-Xin Yan
Journal:  Eur J Neurosci       Date:  2013-02-22       Impact factor: 3.386

3.  Amyloid plaque pathogenesis in 5XFAD mouse spinal cord: retrograde transneuronal modulation after peripheral nerve injury.

Authors:  Jian-Ming Li; Zhi-Qin Xue; Si-Hao Deng; Xue-Gang Luo; Peter R Patrylo; Gregory W Rose; Huaibin Cai; Yan Cai; Xiao-Xin Yan
Journal:  Neurotox Res       Date:  2012-10-05       Impact factor: 3.911

4.  Cytoplasmic fragment of Alcadein α generated by regulated intramembrane proteolysis enhances amyloid β-protein precursor (APP) transport into the late secretory pathway and facilitates APP cleavage.

Authors:  Norio Takei; Yuriko Sobu; Ayano Kimura; Satomi Urano; Yi Piao; Yoichi Araki; Hidenori Taru; Tohru Yamamoto; Saori Hata; Tadashi Nakaya; Toshiharu Suzuki
Journal:  J Biol Chem       Date:  2014-11-18       Impact factor: 5.157

5.  The specific α-neurexin interactor calsyntenin-3 promotes excitatory and inhibitory synapse development.

Authors:  Katherine L Pettem; Daisaku Yokomaku; Lin Luo; Michael W Linhoff; Tuhina Prasad; Steven A Connor; Tabrez J Siddiqui; Hiroshi Kawabe; Fang Chen; Ling Zhang; Gabby Rudenko; Yu Tian Wang; Nils Brose; Ann Marie Craig
Journal:  Neuron       Date:  2013-10-02       Impact factor: 17.173

6.  Amyloidogenic processing of amyloid β protein precursor (APP) is enhanced in the brains of alcadein α-deficient mice.

Authors:  Naoya Gotoh; Yuhki Saito; Saori Hata; Haruka Saito; Daiki Ojima; Chiaki Murayama; Mayo Shigeta; Takaya Abe; Daijiro Konno; Fumio Matsuzaki; Toshiharu Suzuki; Tohru Yamamoto
Journal:  J Biol Chem       Date:  2020-05-27       Impact factor: 5.157

Review 7.  Trafficking in Alzheimer's Disease: Modulation of APP Transport and Processing by the Transmembrane Proteins LRP1, SorLA, SorCS1c, Sortilin, and Calsyntenin.

Authors:  Simone Eggert; Carolin Thomas; Stefan Kins; Guido Hermey
Journal:  Mol Neurobiol       Date:  2017-10-27       Impact factor: 5.590

8.  Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI).

Authors:  Paloma Bermejo-Bescós; Sagrario Martín-Aragón; Karim Jiménez-Aliaga; Juana Benedí; Emanuela Felici; Pedro Gil; José Manuel Ribera; Angel María Villar
Journal:  Neurochem Res       Date:  2013-04-11       Impact factor: 3.996

9.  Mechanism of intramembrane cleavage of alcadeins by γ-secretase.

Authors:  Yi Piao; Ayano Kimura; Satomi Urano; Yuhki Saito; Hidenori Taru; Tohru Yamamoto; Saori Hata; Toshiharu Suzuki
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

10.  Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease.

Authors:  Marta Pera; Daniel Alcolea; Raquel Sánchez-Valle; Cristina Guardia-Laguarta; Martí Colom-Cadena; Nahuai Badiola; Marc Suárez-Calvet; Albert Lladó; Alvaro A Barrera-Ocampo; Diego Sepulveda-Falla; Rafael Blesa; José L Molinuevo; Jordi Clarimón; Isidre Ferrer; Ellen Gelpi; Alberto Lleó
Journal:  Acta Neuropathol       Date:  2012-12-06       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.